Aspen Pharmacare’s turnaround now hinges on its sterile manufacturing, the costly network of injectable-drug plants it must fill. This follows last year’s collapse of a major mRNA contract. CEO Stephen Saad sums up the setback with a farmer’s phrase: “We lost the milk but not the cow.” The contract’s loss blew roughly R2bn out of the manufacturing division’s expected earnings.…
Tag: sterile manufacturing
-
Aspen APAC Divestment Unlocks R26.5 Billion For GLP-1 Focus
Shares in Aspen Pharmacare soared by more than 20% at the close of December, following a major strategic pivot. Africa’s largest drugmaker announced a landmark agreement to sell its entire Asia-Pacific (APAC) operations – excluding China – to Australia’s BGH Capital for A$2.37 billion (around R26.5 billion). The Aspen APAC divestment comes after an unsolicited offer from the private equity…